Literature DB >> 30685820

Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments.

Nancy E Lane1.   

Abstract

PURPOSE OF THIS REVIEW: The goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations. RECENT
FINDINGS: Glucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength. This review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.

Entities:  

Keywords:  Bone cells; Bone vascularity; Glucocorticoids; Osteonecrosis; Parathyroid hormone

Mesh:

Substances:

Year:  2019        PMID: 30685820      PMCID: PMC6839409          DOI: 10.1007/s11914-019-00498-x

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  29 in total

1.  The influence of water removal on the strength and toughness of cortical bone.

Authors:  Jeffry S Nyman; Anuradha Roy; Xinmei Shen; Rae L Acuna; Jerrod H Tyler; Xiaodu Wang
Journal:  J Biomech       Date:  2006       Impact factor: 2.712

2.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

3.  Glucocorticoid dose determines osteocyte cell fate.

Authors:  Junjing Jia; Wei Yao; Min Guan; Weiwei Dai; Mohammad Shahnazari; Rekha Kar; Lynda Bonewald; Jean X Jiang; Nancy E Lane
Journal:  FASEB J       Date:  2011-06-24       Impact factor: 5.191

4.  Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.

Authors:  S Wallach; S Cohen; D M Reid; R A Hughes; D J Hosking; R F Laan; S M Doherty; M Maricic; C Rosen; J Brown; I Barton; A A Chines
Journal:  Calcif Tissue Int       Date:  2000-10       Impact factor: 4.333

5.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Authors:  Kenneth G Saag; Elizabeth Shane; Steven Boonen; Fernando Marín; David W Donley; Kathleen A Taylor; Gail P Dalsky; Robert Marcus
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

6.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

Authors:  N E Lane; S Sanchez; G W Modin; H K Genant; E Pierini; C D Arnaud
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

7.  Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.

Authors:  Wei Yao; Zhiqiang Cheng; Aaron Pham; Cheryl Busse; Elizabeth A Zimmermann; Robert O Ritchie; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-11

8.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David M Reid; Jean-Pierre Devogelaer; Kenneth Saag; Christian Roux; Chak-Sing Lau; Jean-Yves Reginster; Philemon Papanastasiou; Alberto Ferreira; Florian Hartl; Taiwo Fashola; Peter Mesenbrink; Philip N Sambrook
Journal:  Lancet       Date:  2009-04-11       Impact factor: 79.321

9.  Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice.

Authors:  Robert S Weinstein; Chao Wan; Qinglan Liu; Ying Wang; Maria Almeida; Charles A O'Brien; Jeff Thostenson; Paula K Roberson; Adele L Boskey; Thomas L Clemens; Stavros C Manolagas
Journal:  Aging Cell       Date:  2009-12-28       Impact factor: 9.304

10.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Authors:  T P Van Staa; R F Laan; I P Barton; S Cohen; D M Reid; C Cooper
Journal:  Arthritis Rheum       Date:  2003-11
View more
  23 in total

Review 1.  Management of glucocorticoid-induced osteoporosis.

Authors:  Osvaldo D Messina; Luis Fernando Vidal; Maritza Vidal Vidal; Irene E M Bultink; Hennie G Raterman; William Lems
Journal:  Aging Clin Exp Res       Date:  2021-03-22       Impact factor: 3.636

2.  STK11 overexpression prevents glucocorticoid-induced osteoporosis via activating the AMPK/SIRT1/PGC1α axis.

Authors:  Jiao Xiao; Wenjin Li; Guojuan Li; Jiankai Tan; Na Dong
Journal:  Hum Cell       Date:  2022-05-11       Impact factor: 4.174

Review 3.  Nonrespiratory Comorbidities in Asthma.

Authors:  Juan Carlos Cardet; Adeeb A Bulkhi; Richard F Lockey
Journal:  J Allergy Clin Immunol Pract       Date:  2021-09-04

4.  Association between prior cancer diagnosis and osteoporosis: a matched case-control study.

Authors:  Shuman Yang; Na Wang; Jianmeng Wang; Lisa M Lix; William D Leslie; Baoming Yuan
Journal:  Arch Osteoporos       Date:  2022-08-12       Impact factor: 2.879

Review 5.  Osteoimmunology: The correlation between osteoclasts and the Th17/Treg balance in osteoporosis.

Authors:  Fei Huang; Puiian Wong; Jinglan Li; Zheng Lv; Liangliang Xu; Genfu Zhu; Mincong He; Yiwen Luo
Journal:  J Cell Mol Med       Date:  2022-05-28       Impact factor: 5.295

Review 6.  Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature.

Authors:  Lijia Cui; Qian Li; Wenmin Guan; Wei Yu; Xiang Li; Weibo Xia; Yan Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

Review 7.  Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.

Authors:  Thang Dao; Ben Kirk; Steven Phu; Sara Vogrin; Gustavo Duque
Journal:  Calcif Tissue Int       Date:  2021-06-16       Impact factor: 4.333

8.  [Interaction between necroptosis and apoptosis in MC3T3-E1 cell death induced by dexamethasone].

Authors:  Min Feng; Ruirui Zhang; Pei Yang; Kunzheng Wang; Hui Qiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

Review 9.  Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict.

Authors:  M S Rothman; T P Olenginski; I Stanciu; K Krohn; E M Lewiecki
Journal:  Osteoporos Int       Date:  2019-08-31       Impact factor: 4.507

10.  Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan.

Authors:  Satoshi Soen; Miki Kaku; Naoki Okubo; Salsabil Touzeni; Kengo Saito; Makiko Kobayashi
Journal:  J Bone Miner Metab       Date:  2021-06-14       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.